Fantastic hemodynamic numbers.
I've said this before but getting studies started in the US has been like wading through quicksand during the last few years with staffing shortages post-covid and turnover among key hospital staff responsible for approving and implementing studies at each hospital. It's not just with the FDA but each institution brings its own significant bureaucracy and red tape, and cutting through that has become more difficult than ever.
Ann: Montefiore enrolls Patients in US Early Feasibility Study, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.00 |
Change
-0.030(0.50%) |
Mkt cap ! $92.99M | |||
| Open | High | Low | Value | Volume |
| $6.01 | $6.03 | $5.84 | $85.53K | 14.32K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 333 | $6.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.25 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |